Maxpro Capital Acquisition Corp. Stock Price

NasdaqGM:JMAC Community·US$145.2m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create Narrative

JMAC Share Price Performance

US$0

0.00 (0.00%)

US$0

0.00 (0.00%)

US$0

Thu, 11 Jun 26

Share Pricen/a

JMAC Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

5 Risks

0 Rewards

View Full Analysis

Maxpro Capital Acquisition Corp. Key Details

Last Reported Earnings

Sep 30, 2022

Next Reporting Earnings

n/a

: -0.071
: 0%
: 0%
: 0%

View Full Analysis

About JMAC

Founded: 2021
Employees: n/a
CEO: Hong-Jung Chen
Website: n/a

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Recent JMAC News & Updates

Seeking Alpha • Sep 14

Cancer drugmaker Apollomics agrees to go public through SPAC Maxpro Capital

Cancer drugmaker Apollomics agreed to go public through a deal with SPAC Maxpro Capital Acquisition Corp. (NASDAQ:JMAC). JMAC ticked up 1% in premarket trading. The deal values Apollomics at a pre-money equity value of $899 million, according to a statement. Upon close of the deal Apollomics plans to retain $105 million of cash. Apollomics has a pipeline of nine clinical, preclinical and discovery drug candidates that may have the potential to improve treatment of a number of tumor types, according to a press release. The business combination is expected to close in the Q1 and Apollomics is expected to be listed on Nasdaq under the ticker “APLM.” The news was earlier reported by Bloomberg. ARC Group Limited is acting as financial advisor to Maxpro. EF Hutton is acting as capital market advisor to Maxpro. White & Case LLP is acting as legal counsel to Apollomics. Nelson Mullins Riley & Scarborough LLP is acting as legal counsel to Maxpro. Maxpro, a Taiwan based SPAC, raised $104 million in an IPO in October.

Recent updates

No updates

Maxpro Capital Acquisition Corp. Competitors

JMAC Share Price Performance

JMAC Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Maxpro Capital Acquisition Corp. Key Details

About JMAC

Recent JMAC News & Updates

Cancer drugmaker Apollomics agrees to go public through SPAC Maxpro Capital

Recent updates

Maxpro Capital Acquisition Corp. Competitors

Colicity

Atlas Crest Investment II

Gores Holdings VIII

Idea Acquisition